1. Repositório Institucional da UFMG
  2. Publicações Científicas e Culturais
  3. Artigo de Periódico
Please use this identifier to cite or link to this item: http://hdl.handle.net/1843/55707
Full metadata record
DC FieldValueLanguage
dc.creatorWanessa Trindade Clementept_BR
dc.creatorPaulo Henrique Orlandi Mourãopt_BR
dc.creatorJose María Aguadopt_BR
dc.date.accessioned2023-07-03T21:31:54Z-
dc.date.available2023-07-03T21:31:54Z-
dc.date.issued2018-05-08-
dc.citation.volume16pt_BR
dc.citation.issue5pt_BR
dc.citation.spage391pt_BR
dc.citation.epage397pt_BR
dc.identifier.doi10.1080/14787210.2018.1473763pt_BR
dc.identifier.issn14787210pt_BR
dc.identifier.urihttp://hdl.handle.net/1843/55707-
dc.description.resumoIntroduction: The increasing number of transplants performed worldwide and the growing global mobility with migration and travel to and from developing countries and tropical areas are bringing new challenges for the management of transplant infectious diseases, previously less commonly seen, such as Leishmaniasis. However, in this scenario there is a lack of information and the current knowledge is based on a few studies. The selection of the most appropriate treatment depends on various factors, such as patient profile, Leishmania species, disease extent, drug availability, concomitant infections and previous treatments. Therapeutic options may include different formulations of amphotericin B, pentavalent antimonials, miltefosine and paromomycin, among others. These drugs can be used alone or in combination.Areas covered: This review is a practical guide for Visceral Leishmaniasis (VL) specific treatment in solid organ transplant recipients (SOT), including therapeutic options and assessment of therapy response.Expert commentary: The main challenges for treatment of leishmaniasis in SOT recipients are related to the duration of therapy, curative criteria and secondary prophylaxis. Immunosuppression dose reduction is often recommended, but such decisions must be made on an individual basis. At present, Liposomal Amphotericin B is the best choice for treatment and prophylaxis.pt_BR
dc.languageengpt_BR
dc.publisherUniversidade Federal de Minas Geraispt_BR
dc.publisher.countryBrasilpt_BR
dc.publisher.departmentMED - DEPARTAMENTO DE PROPEDÊUTICA COMPLEMENTARpt_BR
dc.publisher.initialsUFMGpt_BR
dc.relation.ispartofExpert Review of Anti-infective Therapy-
dc.rightsAcesso Restritopt_BR
dc.subjectVisceral leishmaniasispt_BR
dc.subjectOrgan Transplantationpt_BR
dc.subject.otherLeishmaniose visceralpt_BR
dc.subject.otherTransplante de orgãospt_BR
dc.titleCurrent approaches to visceral leishmaniasis treatment in solid organ transplant recipientspt_BR
dc.typeArtigo de Periódicopt_BR
dc.url.externahttps://www.tandfonline.com/doi/abs/10.1080/14787210.2018.1473763?journalCode=ierz20pt_BR
dc.identifier.orcidhttps://orcid.org/0000-0003-0848-3740pt_BR
Appears in Collections:Artigo de Periódico

Files in This Item:
There are no files associated with this item.
Show simple item record


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.